You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Non-Hodgkin Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

Not yet recruiting
  • Lymphoma, Non-Hodgkin's, Adult
  • (no location specified)
Aug 4, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Duarte, Hackensack, Houston (SIRPant-M, External-beam

Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • SIRPant-M
  • External-beam radiotherapy (XRT)
  • Duarte, California
  • +2 more
Jul 21, 2023

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

Not yet recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +2 more
  • (no location specified)
Dec 6, 2022

Non Hodgkin Lymphoma Trial in Philadelphia (Pembrolizumab)

Recruiting
  • Non Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abamson Cancer Center of the University of Pennsylvania
Jan 9, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

Advanced Solid Tumors, Relapsed Or Refractory Non-Hodgkin Lymphoma Trial in Zhengzhou, Hangzhou (YH004)

Not yet recruiting
  • Advanced Solid Tumors
  • Relapsed Or Refractory Non-Hodgkin Lymphoma
  • Zhengzhou, Henan, China
  • +1 more
Oct 20, 2022

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in Changsha, Suzhou (U16)

Recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Changsha, Hunan, China
  • +1 more
Mar 13, 2023

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Jinan (CAR-T cells)

Recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +2 more
  • CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jun 14, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Cleveland (Loncastuximab tesirine, Venetoclax)

Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
May 20, 2022

Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

Recruiting
  • Non-Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +3 more
Apr 4, 2023

Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • GIC-102 (Allogeneic NK cells)
  • Gyeonggi-do, Korea, Republic of
  • +3 more
May 18, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023

Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma Trial in Zhengzhou, Shengyang, Hangzhou (HRS-3738)

Recruiting
  • Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
  • Zhengzhou, Henan, China
  • +2 more
Jul 27, 2022

Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)

Not yet recruiting
  • Lymphoma, Non-Hodgkin Lymphoma, B-Cell
  • BAFF CAR-T
  • (no location specified)
Aug 16, 2022

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for

Completed
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Relapsed or Refractory Multiple Myeloma
  • BEBT-908 for injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 9, 2023

Recurrent Histiocytic and Dendritic Cell Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Histiocytic and Dendritic Cell Tumor

Recruiting
  • Recurrent Histiocytic and Dendritic Cell Neoplasm
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Dec 5, 2022

Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Sacramento (biological, radiation, procedure, drug)

Active, not recruiting
  • Refractory Non Hodgkin Lymphoma
  • Relapsed Non Hodgkin Lymphoma
  • rituximab
  • +7 more
  • Sacramento, California
    University of California Davis
Nov 28, 2022